150 related articles for article (PubMed ID: 37327685)
1. Response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Hill C
Eur J Cancer; 2023 Aug; 189():112929. PubMed ID: 37327685
[No Abstract] [Full Text] [Related]
2. Letter re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Guennebaud B; Rivoire A
Eur J Cancer; 2023 Apr; 183():171-173. PubMed ID: 36870191
[No Abstract] [Full Text] [Related]
3. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
4. Response to response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Guennebaud B; Rivoire A
Eur J Cancer; 2023 Nov; 193():113279. PubMed ID: 37678104
[No Abstract] [Full Text] [Related]
5. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Barin-Le Guellec C; Lafay-Chebassier C; Ingrand I; Tournamille JF; Boudet A; Lanoue MC; Defossez G; Ingrand P; Perault-Pochat MC; Etienne-Grimaldi MC
Eur J Cancer; 2020 Jan; 124():37-46. PubMed ID: 31715555
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
7. Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Nies AT; Magdy T; Schwab M; Zanger UM
Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272
[TBL] [Abstract][Full Text] [Related]
8. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine in gastric cancer.
Okines A; Chau I; Cunningham D
Drugs Today (Barc); 2008 Aug; 44(8):629-40. PubMed ID: 18846273
[TBL] [Abstract][Full Text] [Related]
11. Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Zhang H; Shen G; Zhang S; Du F; Cao Y; Jiang J; Zheng F; Ma X; Wang Z; Ren D; Ahmad R; Zhao F; Zhao J
Expert Opin Pharmacother; 2018 Jun; 19(8):795-807. PubMed ID: 29693454
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine in advanced gastric cancer.
Okines A; Chau I; Cunningham D
Expert Opin Pharmacother; 2007 Nov; 8(16):2851-61. PubMed ID: 17956204
[TBL] [Abstract][Full Text] [Related]
14. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database.
Oura M; Oguro F; Agatsuma N; Imamaki H; Nishikawa Y
Cancer Chemother Pharmacol; 2023 Jul; 92(1):7-14. PubMed ID: 37204512
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Saif MW
Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
[TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
Duo-Ji MM; Ci-Ren BS; Long ZW; Zhang XH; Luo DL
Oncotarget; 2017 Jun; 8(23):37896-37911. PubMed ID: 28099947
[TBL] [Abstract][Full Text] [Related]
18. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
20. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
